Ownership and insider activity for Vyome Holdings, Inc. (HIND): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Price
| Price | $2.10 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Jolly Mohanjit | A-Award | 120,000 | $260K |
| 2026-09-01 | Leonard Jerry | |||
| 2025-11-13 | Pomichter Stanley D III | A-Award | 17,833 | $12K |
| 2025-08-15 | Pomichter Stanley D III | |||
| 2025-08-15 | Jolly Mohanjit | A-Award | 454,456 | |
| 2025-08-15 | Jolly Mohanjit | |||
| 2025-11-13 | Tincoff John M. III | A-Award | 17,833 | $12K |
| 2025-11-13 | Sengupta Shiladitya | A-Award | 624,432 | $412K |
| 2025-08-15 | Sengupta Shiladitya | |||
| 2025-11-13 | Nelabhotla Venkateswarlu | A-Award | 615,149 | $406K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.3M | $10.2M | $5.5M | $2.9M | $3.0M | $22.8M | $4.0M | $4.6M | $693000 | $5.0M |
| Short-term Investments | $2.5M | $23.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $143692 | $488613 | $917000 | $4.1M | $2.6M | $2.8M | $2.2M | $1.7M | $1.0M | $98611 |
| Inventory | $1.8M | $2.8M | $984735 | $1.3M | $2.2M | $3.0M | $3.6M | $3.7M | $2.5M | 0 |
| Total Current Assets | $5.7M | $13.9M | $8.7M | $10.1M | $8.9M | $29.9M | $9.9M | $10.3M | $4.6M | $5.4M |
| Property, Plant & Equipment | $201000 | $439000 | $63548 | $774000 | $1.0M | $1.7M | $869000 | $310000 | $154000 | $75821 |
| Goodwill | 0 | $27.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $46.2M | $36.9M | $28.7M | $27.0M | $20.8M | $260000 | 0 | 0 | $314191 |
| Total Assets | $7.0M | $88.7M | $46.3M | $39.7M | $39.7M | $52.5M | $11.3M | $10.7M | $4.8M | $6.5M |
| Accounts Payable | $1.3M | $1.1M | $1.6M | $4.3M | $3.7M | $3.5M | $1.9M | $1.7M | $2.2M | $647533 |
| Short-term Debt | 0 | $2.0M | $9.9M | $1.9M | $3.9M | 0 | $171000 | $111000 | $811000 | $31258 |
| Total Current Liabilities | $1.3M | $1.1M | $8.4M | $10.4M | $11.6M | $7.5M | $7.5M | $3.8M | $5.0M | $2.7M |
| Long-term Debt | $9.9M | $8.0M | 0 | $2.7M | $9.2M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $4.1M | $12.3M | $14.6M | $15.5M | $25.2M | $8.2M | $7.6M | $4.1M | $5.0M | $2.7M |
| Retained Earnings | -$300.9M | -$334.8M | -$419.0M | -$493.2M | -$514.8M | -$578.0M | -$624.2M | -$635.6M | -$642.7M | -$87.6M |
| Total Equity | $2.9M | $76.4M | $31.7M | $24.1M | $14.5M | $44.3M | $3.7M | $6.7M | -$253000 | $2.4M |
| Total Debt | $143692 | $488613 | $6.3M | $5.4M | $13.3M | $279000 | $171000 | $262000 | $967000 | $31258 |
| Net Debt | -$3.2M | -$9.7M | $762465 | $2.5M | $10.2M | -$22.5M | -$3.8M | -$4.3M | $274000 | -$5.0M |
| Working Capital | $4.4M | $12.8M | $356492 | -$280000 | -$2.7M | $22.4M | $2.4M | $6.5M | -$397000 | $2.7M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 4.37 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -18.08 |
Profitability
| Return on Equity | -254.62% |
| Return on Invested Capital | -57.53% |
| Return on Assets | -123.23% |
| Gross Margin | 46.50% |
| Operating Margin | -3250.25% |
| Net Margin | -8716.77% |
Related companies: ARMP · CCCC · CDXS · CGEN · IMDX · IPHA · NVCT
Explore sector: Healthcare · Biotechnology
More sections of HIND: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks